INDUSTRY RESEARCH SHOWCASE
Publication #0176Advancing liver care
Together
Meet the Resolution Therapeutics team at AASLD, Denver to discuss our clinical program.
Booth #2266/Upper-Level Exhibit Hall
- Friday 6 November5:00–6:30 PM
- Saturday 7 November9:30 AM–5:30 PM
- Sunday 8 November9:30 AM–5:30 PM
THE CLINICAL PROGRAM
A regenerative approach
to liver disease
Resolution Therapeutics is a clinical-stage biopharmaceutical company pioneering Regenerative Macrophage Therapy (RMT) in inflammatory and fibrotic diseases.
Our clinical program uses an engineered regenerative macrophage therapy in development for people with liver cirrhosis who have recovered from a recent hepatic decompensation, and patients with recent-onset medically refractory ascites.
This population has high mortality and no disease-modifying therapy available.

Building on our experience, our next clinical trial HORIZON-RMT will be initiated in 2027; we would like to hear from experienced hepatologists, and clinical trial centers interested in taking part.
OUR CLINICAL PROGRAM
EMERALD is the third clinical trial showing Regenerative Macrophage Therapy benefit with 50+ patients, and is a leading step in our work towards an engineered, scalable therapy for people with advanced liver disease

Your perspective
Our next horizon
We are building partnerships across the liver disease community, from academic medical centers, clinical trial sites and community sites, to patient organizations and care providers. Your perspective can help shape what comes next.
Explore partnershipLET’S DISCUSS
Patient Needs
Understanding the clinical realities and unmet needs of people living with decompensated cirrhosis.
Cell Therapy
Supporting the latest scientific endeavors to bring an autologous cell therapy from development to patients.
Partnerships
How we might work together as our clinical program progresses through development.
THE SCIENCE IN DENVER
Join the discussion
Two presentations.
One regenerative approach.
LATE-BREAKING POSTER
Publication #5034Regenerative Macrophage Therapy (RMT) in End-Stage Liver Disease: Early Results from the EMERALD/OPAL Trials
RESOLUTION THERAPEUTICS
Meet our team at AASLD, Denver
Amir Hefni
Chief Executive Officer
Cliff Brass
Chief Medical Officer
Faisal Sheikh
Medical Director
Louise Rowe
VP Strategy and Operations
Camille Perrin
Senior Clinical Project Manager
Lara Campana
Senior VP, Research & Translational Sciences
For any enquiries please reach out: contact@resolution-tx.com
LET’S CONNECT
Start a
conversation
Interested to learn more about RMT as a potential treatment for decompensated cirrhosis?
Tell us how you’d like to connect with the Resolution team.
Meet us at AASLD, request a follow-up call after AASLD The Liver Meeting, or register your interest in a potential study-site partnership.
Not at AASLD this year?
We’d still like to hear from you. Book a video call with our clinical team to discuss opportunities for site participation.
For healthcare professionals and research centers. This form is an expression of interest, not a confirmed appointment or a study-site commitment.
